Founded in 1929 as a family business, Ipsen has almost a century of experience and expertise and focuses in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Ipsen’s Milestones
March 2023
Ipsen acquires Albireo
Ipsen acquires rare liver disease specialist Albireo, bringing into its portfolio Bylvay® (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of pediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC).
August 2022
Epizyme acquired
Ipsen successfully completed the acquisition of Epizyme and its lead medicine, Tazverik®(tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory follicular lymphoma (FL), which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. As part of the transaction, Ipsen also acquired Epizyme’s first-in-class, oral SETD2 inhibitor development candidate.
July 2022
Consumer HealthCare divested
In February 2022, Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler. In July, Ipsen completed the divestment of the CHC business to Mayoly Spindler.
2019
Boosting Ipsen’s capacities in Rare Disease
Ipsen acquired Montreal-based Clementia Pharmaceuticals, specializing in rare bone diseases, Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).
2017
Treatment approvals and asset acquisitions.
The Dysport Injection was approved in the United States for the treatment of lower limb spasticity in children aged two years and older. Ipsen also licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January the following year, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde®, for the treatment of pancreatic and ovarian cancer.
